|Articles|July 20, 2016
JSS Selects OmniComm TrialMaster EDC
Advertisement
Fort Lauderdale, FL - OmniComm Systems Inc., a global leading provider of clinical data management technology, today announced the signing of a three-year agreement with JSS Medical Research, a leading global contract research organization (CRO) based in Montréal, Québec, Canada. OmniComm’s TrialMaster electronic data capture (EDC) suite will be used for the collection of clinical data over a three-year term in numerous trials spanning Phase I to Phase III, post-marketing observational, patient registries, and medical device clinical studies conducted across global investigative sites. TrialMaster was selected as JSS Medical Research’s standard EDC platform replacing its legacy EDC applications. TrialMaster was chosen after a comprehensive evaluation of other leading EDC solutions. “We’re very pleased to continue our longstanding relationship with OmniComm. We found the TrialMaster product to be the best overall solution for the varied needs of our global teams and our clients,” said Stella Boukas, Chief Operations Officer, JSS Medical Research Inc. Michel Bordeleau, Global Director of Information Technologies added: “The selection process involved key stakeholders in our business, from senior management to clinical operations, including data management, and OmniComm passed muster in every department.” Specific emphasis for selection was placed on:
- Ability to build studies more efficiently and effectively than its legacy systems
- Adeptness in query management workflow
- Intuitive interface for all key user groups
- Ease and timeliness of data extraction into SDTM submission ready data format
TrialMaster will be deployed within OmniComm’s
OmniCloud
for hosting and maintenance of the entire IT infrastructure, ensuring clinical data management technology is always running; data is secure, and product enhancements are rolled out seamlessly. “We are truly excited about JSS Medical’s decision adopt enterprise enablement with TrialMaster EDC. It was a tough evaluation run by a technology savvy group,” said Kuno van der Post, SVP of business development, OmniComm Systems. “Canada and Latin America are increasingly important geographic markets for OmniComm and so, as we grow throughout all of the Americas, we will look more and more to JSS Medical Research as a valued partner.”
Supporting Information
About JSS Medical Research
JSS Medical Research is a global Contract Research Organization (CRO) with offices currently in Canada, USA, Colombia, India, and Poland. The company offers comprehensive clinical trial management services, from study design to publication of results, in Phase I-IV trials across a broad range of therapeutic areas. Biotechnology companies rely on the company’s knowledgeable project teams, and its customer-centric and flexible approach to successfully conduct their critical early phase trials, while pharmaceutical companies can leverage its niche post-marketing service offerings. With science and clinical epidemiological expertise at its core, JSS Medical Research is a leader in Post-Approval Clinical Epidemiology Studies (PACES) including Post-Marketing Observational Studies, Health Outcomes Research and Health Economics. Currently JSS Medical Research is conducting research studies in over 20 countries around the world for its clients, which include the top 25 global pharmaceutical companies and biotechnology/device companies, worldwide. For more information, visit
www.jssresearch.com
About OmniComm Systems, Inc.
OmniComm Systems, Inc. is a leading strategic software solutions provider to the life sciences industry. OmniComm is dedicated to helping the world’s pharmaceutical, biotechnology, contract research organizations, diagnostic and device firms, and academic medical centers maximize the value of their clinical research investments. Through the use of innovative and progressive technologies these organizations drive efficiency in clinical development, better manage their risks, ensure regulatory compliance and manage their clinical operations performance. OmniComm provides comprehensive solutions for clinical research with an extensive global experience from over 4,000 clinical trials. For more information, visit
www.omnicomm.com
.
Newsletter
Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.
Advertisement
Related Articles
- eClinical Technology: Misconceptions, Challenges, and Opportunities
September 9th 2025
- How Sponsors Can Modernize Tools to Support Physicians
September 9th 2025
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
AstraZeneca’s Tagrisso Shows Landmark Overall Survival Benefit in Non-Small Cell Lung Cancer
2
Phase III EMPOWER-Lung 3 Trial Confirms Five-Year Survival Benefit With Libtayo Plus Chemotherapy in NSCLC
3
Investigational OX40-Targetting T-Cell Therapy Shows Durable Efficacy Treating Atopic Dermatitis in Phase III Trial
4
Pfizer, BioNTech’s Comirnaty Shows Strong Immune Response in Phase III Trial for COVID-19
5